ENTPD3 and breast carcinoma: In this study, by reducing the hydrolase activity of ENTPD3 through site-directed mutagenesis and observing the effect of the mutated ENTPD3 on cell processes at cellular and animal levels, we proved that ENTPD3 also inhibited the progression of breast cancer by degrading eATP.